Intact Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 13

Intact Therapeutics General Information

Description

Developer of smart gels intended to treat gastrointestinal disorders. The company's product offerings mainly include a therapeutic specialized gel that is liquid at room temperature but becomes a mucoadhesive gel at body temperature, targeting ulcerative colitis and other conditions of the gastrointestinal tract and the gel technology provides significantly localized concentrations of drug and minimizes systemic exposure, facilitating retention, efficacy and comfort, enabling patients with inflammatory bowel illness to get access to the painless healing procedure.

Contact Information

Website
www.intacttherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2627 Hanover Street
  • Palo Alto, CA 94304
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 2627 Hanover Street
  • Palo Alto, CA 94304
  • United States
+1 (650)

Intact Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intact Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private Completed Clinical Trials - Phase 1
10. Grant 08-May-2024 Completed Clinical Trials - Phase 1
9. Accelerator/Incubator 01-Oct-2023 Completed Clinical Trials - Phase 1
8. Grant 01-Jan-2023 Completed Clinical Trials - Phase 1
7. Grant 28-Jan-2022 Completed Clinical Trials - Phase 1
6. Grant 01-Jan-2020 Completed Clinical Trials - Phase 1
5. Seed Round 01-Sep-2019 Completed Clinical Trials - Phase 1
4. Accelerator/Incubator 23-Jul-2019 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 12-Jul-2019 $3.15M Completed Clinical Trials - Phase 1
2. Seed Round 29-Mar-2019 $3M $3.15M Completed Clinical Trials - Phase 1
To view Intact Therapeutics’s complete valuation and funding history, request access »

Intact Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed
Seed-1
To view Intact Therapeutics’s complete cap table history, request access »

Intact Therapeutics Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Intact Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4472640-A1 Mesalamine pharmaceutical formulations and methods of use thereof Pending 04-Feb-2022
EP-4472640-A4 Mesalamine pharmaceutical formulations and methods of use thereof Pending 04-Feb-2022
US-20250090552-A1 Mesalamine pharmaceutical formulations and methods of use thereof Pending 04-Feb-2022
WO-2023150345-A1 Mesalamine pharmaceutical formulations and methods of use thereof Inactive 04-Feb-2022
US-20210361602-A1 Dosing methods for treating inflammatory bowel conditions Pending 22-May-2020 A61P1/00
To view Intact Therapeutics’s complete patent history, request access »

Intact Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intact Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
VentureWell Accelerator/Incubator Minority
California Institute for Regenerative Medicine Government
US National Science Foundation Accelerator/Incubator
QB3 Accelerator/Incubator Minority
Angel (individual) Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

Intact Therapeutics FAQs

  • When was Intact Therapeutics founded?

    Intact Therapeutics was founded in 2015.

  • Where is Intact Therapeutics headquartered?

    Intact Therapeutics is headquartered in Palo Alto, CA.

  • What is the size of Intact Therapeutics?

    Intact Therapeutics has 5 total employees.

  • What industry is Intact Therapeutics in?

    Intact Therapeutics’s primary industry is Drug Discovery.

  • Is Intact Therapeutics a private or public company?

    Intact Therapeutics is a Private company.

  • What is Intact Therapeutics’s current revenue?

    The current revenue for Intact Therapeutics is .

  • How much funding has Intact Therapeutics raised over time?

    Intact Therapeutics has raised $4.65M.

  • Who are Intact Therapeutics’s investors?

    VentureWell, California Institute for Regenerative Medicine, US National Science Foundation, QB3, and are 5 of 13 investors who have invested in Intact Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process